Loading
A phase 2/3 trial testing GRT-C901 in colorectal cancer, active and no longer recruiting.
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer is a phase 2/3 interventional study registered as NCT05141721, led by Seattle Project, and active but no longer recruiting on the registry. Official title: A Phase 2/3, Randomised, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer. Planned enrolment is 700 participants (estimated). The study started in 2022-02-12 and primary completion is expected in 2027-03. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GRT-C901, GRT-R902, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/